9 research outputs found

    Nutrient Removal from Recirculating Aquaculture System Water

    Get PDF
    Recirculating aquaculture systems (RAS), where only approximately 10% of the total system water is exchanged per day, have grown in popularity in recent years due to their potential to provide a high-quality protein source in a contained environment. With increased production comes the need for RAS water treatment to mitigate recirculation and discharge of nutrients produced by fish; mainly phosphorus and nitrogen. When discharged, nutrients can contribute to eutrophication in surrounding water bodies, harming the fish and other aquatic life. Therefore, RAS effluent should be treated before discharge. One method of phosphorus removal is adsorption, a surface phenomenon that is often used to bind dissolved pollutants to a solid-phase medium and remove them from water. Nitrogen is present in RAS as ammonia, which is toxic to fish even at concentrations as low as 0.05 mg L-1. Therefore, the ammonia is transformed to nitrogen’s non-toxic form, nitrate, before recirculation or discharge, by a process called nitrification. Both adsorption and nitrification can be affected by RAS process parameters such as salinity. Many anadromous fish such as Atlantic salmon require a change in salinity over their lifetimes; therefore, both of these processes should be investigated for their response to salinity changes. An adsorption study was performed on an aluminum oxide-based material, RhizoSorb®, to assess its response to different RAS variables. It was found that both film diffusion and intraparticle diffusion are rate-controlling steps in the adsorption process, and the removal efficiencies in batch tests were affected by time, salinity, and phosphate concentration. The Freundlich isotherm fit the equilibrium data better than the Langmuir isotherm, showing that adsorption is a multi-layer process and that the adsorbent is highly heterogeneous. The Clark model was better suited than the Thomas model for predicting the performance of the RhizoSorb® in a flow-through system. The results of this study showed that RhizoSorb® and other alumina-based sorbents have high potential towards application to the RAS water treatment process to remove and recover phosphorus. A second study was performed to assess the effects of salinity changes on nitrifying biofilters. Acclimation to a small amount of salinity before transition to a higher salinity may help biofilters recover from the larger shift; therefore, a series of experiments was performed on both freshwater and brackish (3 parts per thousand (ppt)) biofilters to assess their respective levels of recovery after an abrupt change in salinity (3, 20, and 33 ppt). Tests were run for a two-week period in which the nitrification rates were monitored. The freshwater biofilters quickly recovered from a shift to 3 ppt, but did not recover from a shift to 20 or 33 ppt. The brackish filters started to recover at the end of the two-week test, but did not recover from a shift to 33 ppt. DNA sequencing of the variable V4 region of the 16s rRNA gene showed that the heterotrophic communities in the biofilm were lysed at a greater proportion than the nitrifiers, though the nitrifiers were inactivated in higher salinities. A longer series of tests could fully characterize the effects of acclimation to salinity with the effects of ammonia concentration and organic matter, which could help to fully understand the microbial community dynamics

    Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

    No full text
    Background: COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs). Objectives: The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality. Methods: Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions. Results: The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51). Conclusion: In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings

    The value of open-source clinical science in pandemic response: lessons from ISARIC

    No full text
    International audienc

    The value of open-source clinical science in pandemic response: lessons from ISARIC

    No full text

    Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

    No full text
    Background: COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs). Objectives: The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality. Methods: Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions. Results: The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51). Conclusion: In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings

    Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

    Get PDF
    Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death

    ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    No full text
    The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing comorbidities, vital signs, chronic and acute treatments, complications, dates of hospitalization and discharge, mortality, viral strains, vaccination status, and other data. Here, we present the dataset characteristics, explain its architecture and how to gain access, and provide tools to facilitate its use
    corecore